Current research protocols

Dual GIP and GLP-1 receptor agonist studied for metabolic and body-composition endpoints.

Typical dose

2.5 mg → titrated to 5–15 mg

Cadence

Once weekly

Cycle

Titrate every 4 weeks; 12–72 week studies

Route

Subcutaneous

Notes: Titration is used to mitigate GI side effects. Do not exceed 15 mg/week in study protocols without clinical oversight.

Triple agonist under investigation for weight-loss and hepatic endpoints; steeper titration than tirzepatide.

Typical dose

2 mg → titrated to 4–12 mg

Cadence

Once weekly

Cycle

48 weeks in Phase II trials

Route

Subcutaneous

Notes: GI side effects are dose-dependent; slow titration is standard in current trials.

Selective GLP-1 receptor agonist with the largest published clinical dataset among incretin peptides.

Typical dose

0.25 mg → titrated to 1–2.4 mg

Cadence

Once weekly

Cycle

Titrate every 4 weeks; long-term studies to 68+ weeks

Route

Subcutaneous

Notes: STEP trial protocols escalate by 0.25 mg increments monthly.

Body Protection Compound derived from a gastric peptide; studied for tendon, ligament, and GI models.

Typical dose

250–500 mcg

Cadence

1–2× daily

Cycle

4–8 weeks on / 4 weeks off

Route

Subcutaneous (local to injury site preferred in animal studies)

Notes: Frequently paired with TB-500 in regenerative research stacks.

Commonly stacked with: TB-500, GHK-Cu

Actin-binding peptide investigated for cardiac, tendon, and wound-healing models.

Typical dose

2–5 mg loading; 2 mg maintenance

Cadence

2× weekly loading × 4 weeks; then 1× weekly

Cycle

6–8 weeks

Route

Subcutaneous or intramuscular

Notes: Loading phase is protocol-typical; drop to maintenance after 4 weeks.

Commonly stacked with: BPC-157

Selective GHRP with minimal effect on cortisol/prolactin in study models.

Typical dose

200–300 mcg

Cadence

2–3× daily (AM, pre/post-workout, pre-bed)

Cycle

8–12 weeks on / 4 weeks off

Route

Subcutaneous

Notes: Often paired 1:1 with CJC-1295 (no DAC) for pulsatile GH release studies.

Commonly stacked with: CJC-1295 (no DAC)

Short-half-life GHRH analog (Mod GRF 1-29) used to amplify GH pulses when paired with a GHRP.

Typical dose

100 mcg

Cadence

2–3× daily with a GHRP

Cycle

8–12 weeks on / 4 weeks off

Route

Subcutaneous

Notes: Without DAC, the compound has a short half-life (~30 min) — pairs stoichiometrically with ipamorelin at each pulse.

Commonly stacked with: Ipamorelin

Mitochondrial-derived peptide studied for metabolic and exercise-adaptation endpoints.

Typical dose

5–10 mg

Cadence

2–3× per week

Cycle

4–8 weeks

Route

Subcutaneous

Notes: Studies commonly cluster injections on non-consecutive days.

hGH C-terminal fragment (176-191) studied for lipolytic activity without GH/IGF-1 effects.

Typical dose

300 mcg

Cadence

Once daily, AM fasted

Cycle

8–12 weeks

Route

Subcutaneous

Notes: Fasted-state administration is standard in the published protocols.

Copper tripeptide studied for wound-healing, dermal remodeling, and hair-follicle endpoints.

Typical dose

1–2 mg (SC); topical variants common in skin studies

Cadence

Daily

Cycle

8–12 weeks

Route

Subcutaneous or topical

Notes: Do not co-administer in the same syringe as reducing agents.

Cardiolipin-targeted peptide investigated for mitochondrial function in cardiac and neurologic models.

Typical dose

1–5 mg

Cadence

Daily

Cycle

4–12 weeks

Route

Subcutaneous

Notes: Reconstituted volumes are small; use a low-volume syringe for accuracy.

Long-acting amylin analog investigated alongside GLP-1 agonists for appetite/weight endpoints.

Typical dose

0.3 mg → titrated to 2.4 mg

Cadence

Once weekly

Cycle

20+ weeks in trial protocols

Route

Subcutaneous

Notes: Frequently studied in combination with semaglutide (CagriSema).

Commonly stacked with: Semaglutide

ACTH(4-10) analog studied for cognitive and neuroprotective endpoints.

Typical dose

300–600 mcg per nostril

Cadence

1–3× daily

Cycle

2–4 weeks

Route

Intranasal

Notes: Split total daily dose across both nostrils; short cycles are protocol-typical.

Tuftsin analog investigated for anxiolytic and immunomodulatory endpoints.

Typical dose

250–500 mcg per nostril

Cadence

1–3× daily

Cycle

2–4 weeks

Route

Intranasal

Notes: Often alternated with Semax in nootropic research stacks.

Commonly stacked with: Semax

Blend of Kisspeptin, TB-500-like fragment, GHK-Cu, and BPC-157 studied for combined regenerative endpoints.

Typical dose

1–2 mg blend equivalent

Cadence

Daily to 5× per week

Cycle

4–8 weeks

Route

Subcutaneous

Notes: Because it is a blend, dose the total volume — each component's mg is set by the blend ratio.

Nicotinamide adenine dinucleotide studied for cellular energetics and longevity models.

Typical dose

50–100 mg

Cadence

Daily loading × 7–14 days; then 2–3× weekly

Cycle

4–12 weeks

Route

Subcutaneous or intramuscular

Notes: Flushing and injection-site discomfort are dose-dependent; slow-push technique is standard.